首頁 >> 供求商機
| 產(chǎn)品英文名稱 | Mouse G-CSF protein |
| 產(chǎn)品中文名稱 | 重組小鼠粒細胞集落刺激因子（G-CSF) |
| 別名 | G-CSF; Colony Stimulating Factor 3; Granulocyte; GCSF |
| 標簽 | 無標簽 |
| 表達宿主 | 大腸桿菌 |
| 種屬 | 小鼠 |
| 序列 | 氨基酸序列來源于：重組小鼠粒細胞集落刺激因子（G-CSF) (P09920) (V31-A208) 表達的蛋白片段。 |
| 活性 | 通過其誘導M-NFS-60細胞增殖的能力來測定。ED50為2.038 pg/mL。 |
| 蛋白長度 | 重組小鼠粒細胞集落刺激因子（G-CSF) 由178個氨基酸組成，預測分子量為18.95 KD。 |
| 純度 | > 99% ，使用SDS-PAGE檢測 |
| 特點&優(yōu)勢 | 通過LAL法測定，每微克蛋白里內(nèi)毒素含量<1.0> |
| 產(chǎn)品形式 | 凍干粉，凍干緩沖液為無菌的20 mM Tris，150 mM NaCl，pH 7.4。 |
| 基因ID | 12985 |
| 蛋白序列鏈接 | /uniprotkb/P09920/entry |
| 使用中注意事項 | 開蓋使用前，請先離心。本產(chǎn)品為凍干粉，推薦用該產(chǎn)品配套的Reconstitution Buffer進行復溶，且濃度不低于100 µg/mL。客戶可根據(jù)后續(xù)的實驗需求，進行進一步的稀釋。 |
| 保存建議 | 本產(chǎn)品為凍干粉形式，建議：將凍干粉產(chǎn)品保存于-20℃以下的干燥環(huán)境中。本產(chǎn)品溶解之后，可在4℃保存2-7天，長期使用請置于-20℃以下。為長期保存，推薦添加載體蛋白（0.1% HAS/BSA或12%FBS），并酌情分裝保存，避免反復凍融。 |
| 運輸條件 | 冰袋運輸（藍冰） |
| 警告 | 本文列出的產(chǎn)品僅供研究使用，不適用于人類或臨床診斷。我們產(chǎn)品所推薦應(yīng)用，不是建議使用我們的產(chǎn)品去違反任何或許可證。對于使用本產(chǎn)品可能發(fā)生的侵權(quán)或其他違規(guī)行為，我們不承擔任何責任。 |
| 背景 | Granulocyte-colony stimulating factor (G-CSF) is a growth factor and an essential cytokine belonging to the CSF family of hormone-like glycoproteins. It is produced by numerous cell types including immune and endothelial cells. G-CSF binding to its receptor G-CSF-R which belongs to the cytokine receptor type I family depends on the interaction of alpha-helical motifs of the former and two fibronectin type III as well as an immunoglobulin-like domain of the latter. Recent animal studies have also revealed that G-CSF activates multiple signaling pathways, such as Akt and also the Janus family kinase-2 and signal transducer and activation of transcription-3 (Jak2-STAT3) pathway, thereby promoting survival, proliferation, differentiation and mobilisation of haematopoietic stem and progenitor cells. G-CSF is a cytokine that have been demonstrated to improve cardiac function and perfusion in myocardial infarction. And it was initially evaluated as a stem cell mobilizer and erythropoietin as a cytoprotective agent. G-CSF prevents left ventricular remodeling after myocardial infarction by decreasing cardiomyocyte death and by increasing the number of blood vessels, suggesting the importance of direct actions of G-CSF on the myocardium rather than through mobilization and differentiation of stem cells. Accordingly, recombinant human (rh)G-CSF has been extensively used in clinical haematology and oncology to enable bone marrow transplantation or to treat chemotherapy-associated neutropenia. In preclinical study, G-CSF improved cardiac function and perfusion by angiomyogenesis and protection of cardiomyocytes in myocardial infarction. |
Fig.Mouse G-CSF protein
1